Europes AI Trade Dependency Could Pose Strategic Risks Report Warns Kidnapping in France Leads to Crypto Wallet in Venezuela Ransom Laundering Scheme Exposed AARP Releases April 2026 Employment Data Digest Trends for Older Workers Under Review SNC Scandic Coin Expands Market Reach Regulated RealWorld Asset Project Lists on Major Exchanges Meta Settles Test Case Social Media Addiction Lawsuit with US School District China Industrial Profits Surge 247 in April Marking Fastest Growth in Over Two Years KRG Q1 2026 Earnings EPS Miss of 6377 Raises Questions MED Q1 2026 Earnings EPS Surpasses Estimates Amid Cost Management Efforts SFB Q1 2026 Earnings Slight EPS Beat on Core Operations Kalaris Therapeutics Q1 2026 Earnings NarrowerThanExpected Loss Highlights Cost Discipline Amid PreRevenue Biotech PENN Q1 2026 Earnings EPS Misses Estimates as Company Reports Adjusted Loss JBS Q1 2026 Earnings EPS Miss Pressures Shares as Cost Headwinds Persist Grove Collaborative Holdings GROV Inches Higher as Stock Hovers Near Resistance FACT II Acquisition Corp FACT Holds Steady at 1066 Amidst Flat Trading Session Newsmax NMAX Edges Higher Holds Above Key Support Level ProKidney Corp PROK Jumps Over 7 as Biotech Stock Tests Resistance at 190 Steel Dynamics STLD Holds Gains as Steel Demand Stabilizes Treasury Yield Surge Challenges RiskFree Label Shifts Focus to Intermediate and Corporate Bonds Chesapeake Utilities Corporation Q1 2026 Earnings Earnings Beat Expectations Stock Slips Slightly ZOOZ Strategy Ltd ZOOZ Surges 858 as It Nears Key Resistance Level OEC Q1 2026 Earnings EPS Misses Estimates Sharply Stock Rises Despite Loss Mount Logan Capital Inc Q1 2026 Earnings Loss Per Share of 051 Amidst Market Headwinds Bioceres Crop Solutions BIOX Q1 2026 Earnings Significant EPS Miss Weighs on Shares DBRG Q1 2026 Earnings EPS Misses Estimates Amid Mixed Market Response Solana Company HSDT Q1 2026 Earnings Deep EPS Miss Triggers Stock Decline Amid Undisclosed Revenue Fortis Inc FTS Q1 2026 Earnings Modest EPS Miss Amid Steady Utility Performance NervGen Pharma Q3 2025 Earnings Narrowed Loss Meets Estimates But Stock Plunges 43